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Protective immunity against lethal HSV-1 challenge
in mice by nucleic acid-based immunisation with
herpes simplex virus type-1 genes specifying
glycoproteins gB and gD
ABOLGHASEM BAGHIAN, VLADIMIR N. CHOULJENKO, OSWALD D’AUVERGNE ,
MARK J. NEWMAN{{, SALMAN BAGHIAN and KONSTANTIN G. KOUSOULAS
Department of Veterinary Microbiology and Parasitology, School of Veterinary Medicine, Louisiana State
University, Baton Rouge, LA 70803,  Department of Biological Sciences, Southern University, Baton Rouge,
LA 70813 and {Vaxcel, Norcross, GA, USA

DNA-based vaccines were employed to assess protective immunity against herpes simplex
virus in experimental infections of hairless (strain SKH1) and BALB/c mice. Mice were
vaccinated with plasmids containing the herpes simplex virus type-1 (HSV-1) glycoprotein B (gB) or D (gD) genes under the human cytomegalovirus immediate-early
promoter control. Vaccines were injected intramuscularly (i.m.) or intraperitoneally (i.p.)
as purified DNA alone or as formulations supplemented with different non-ionic block
copolymers. Antibody responses were assessed by immunofluorescence and radioimmunoprecipitation assays. Mice inoculated with either gB or gD plasmid, alone or
with non-ionic block copolymers CRL 1029 and CRL 1190, produced high levels of
antibodies specific for gB or gD. Three weeks after the last vaccination, mice were
challenged with a clinical HSV-1 isolate (ABGK-1) by inoculation of a shaved and
subsequently scarified area between the third and fourth lumbar vertebrae. Mice
immunised with either gD or gB plasmid alone or mixed with copolymers were
protected against lethal HSV-1 challenge when immunisation was performed via the i.m.
route. Immunisations given via the i.p. route induced humoral responses in some mice
and protected the animals against lethal HSV-1 challenge only when the formulations
contained copolymers. The BALB/c mouse model was shown to be as good a model as
the hairless mouse model.

Introduction
Herpesviruses are the causative agents or co-factors of
important human and animal diseases, including certain
cancers. They possess the unique ability to remain
latent and can be reactivated causing severe or chronic
diseases [1]. Conventional methods of generating protective immunity against infectious agents have relied
on the use of attenuated or killed viruses or
recombinant components of the viruses. All of these
approaches have limitations that reduce their usefulness
as vaccines. For example, attenuated pathogens have
inherent risks that may limit their use in man [2].
Vaccines based on killed viruses can induce strong
Received 11 June 2001; revised version received 3 Oct.
2001; accepted 30 Oct. 2001.
Corresponding author: Dr A. Baghian.
{Present address: Epimmune, San Diego, CA, USA.

antibody responses; however, generally, they are unable
to induce MHC class I-restricted responses. As the
incidence of herpes continues to increase in the
population, and as new strains of the virus resistant
to chemotherapy continue to emerge, so does the need
for a safe and effective vaccine.
At least 11 virus-specified glycoproteins are found on
the surface of the herpes simplex virus (HSV) virion
and in the plasma membranes of HSV-infected cells
and serve as important targets of humoral and cellular
immunity [3–5]. They are designated as gB, gC, gD,
gE, gG, gH gI, gJ, gK, gL and gM. Viral glycoproteins
gB, gD and gC, the most abundant proteins, are the
primary elements of vaccine efforts to combat HSV
infections. Recombinant baculoviruses were used to
express gB and gD. When these glycoproteins were
used as vaccines, they induced high levels of protective
immunity against lethal viral challenge in BALB/c
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mice [6, 7]. Immunopurified gD and gB and truncated
forms of these glycoproteins have been used to induce
protective immune responses in mice and other animal
models [8–13].
An observation in 1990 showed that direct introduction
of plasmid DNA encoding specific antigens can be
taken up by muscle cells and be expressed [14]. DNA
vaccination against various pathogens, including human
immunodeficiency virus (HIV) [15, 16], bovine herpes
virus [17], influenza [18–20], rabies virus [21],
hepatitis B virus [22] and malaria [23] have been
evaluated as vaccines in several animal models. Vaccination of mice via intranasal and intramuscular routes
with plasmid DNA expressing HSV-1 gB induced protection against HSV-1 challenge through a
vaginal route of infection [24]. Protection of mice or
guinea-pigs against systemic or vaginal infections with
HSV-1 or HSV-2 viruses by DNA vaccination with
HSV-1 or HSV-2 gB or gD genes has been reported
[25, 26]. Similarly, it was shown that mice immunised
intramuscularly (i.m.) with plasmid DNA encoding
equine herpesvirus 1 glycoprotein D (EHV-1 gD) were
protected against intranasal challenge with EHV-1 [27].
Intraperitoneal vaccinations have not been used frequently to assess vaccination potential. In one case,
mice vaccinated intraperitoneally (i.p.) with DNA
plasmids coding for the Coccidioides immitis Ag2
were protected against infectious challenge with C.
immitis [28].
Non-ionic block copolymers comprise a single chain
of hydrophobic polyoxypropylene (POP) sandwiched
between two hydrophilic chains of polyoxyethylene
(POE). Copolymers have been used as vaccine adjuvants and as anti-infective agents for the treatment of
established bacterial and viral infections in formulations based on protein antigens [29–31]. The adjuvant
activity of non-ionic block copolymers is influenced by
both size and POE content. As the size of the POP core
is increased, so is the adjuvant activity of the
copolymer, and peak activity is achieved with copolymers with POP cores that are 12–15 kDa. Maximal
adjuvant activity is also correlated with low POE
content, 5–10% is optimal [29–31].
Induction of humoral immune responses generated by
DNA-based vaccination with plasmids expressing gB and
gD genes injected i.p. or i.m. was investigated in this
study. The vaccination was performed with or without
non-ionic block copolymers. The protective efficacy of
these vaccines, with or without copolymers, was evaluated by challenging the mice with a lethal dose of HSV-1.

Materials and methods
Virus, cells and media
HSV-1 ABGK-1 was isolated from a cold sore lesion of
a male individual who was otherwise healthy. The virus
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was propagated in African green monkey kidney (Vero)
cells and viral stocks were made after the third
passage. Vero cells were propagated in Dulbecco’s
modification of Eagle’s medium (DMEM) supplemented with heat-inactivated fetal bovine serum 10%. The
virus was confirmed as HSV-1 by indirect immunofluorescence with an HSV-1 specific monoclonal antibody (MAb).

Mice
Female BALB/c and hairless (strain SKH-1) mice were
purchased from Harlan Sprague-Dawley (Indianapolis,
IN, USA). The hairless mouse is a good model for
induction of zosteri form lesions by HSV-1; otherwise,
no immunological deficiency has been associated with
this strain of mouse. Mice used in this study were
typically 8–12 weeks old and were bred in the
Laboratory Animal Research Facility of the School of
Veterinary Medicine, Louisiana State University.

Plasmid constructs
A 3.7-kb HindIII DNA fragment containing the gB
gene [32] and a 1.8-kb HindIII DNA fragment containing the gD gene [33] were cloned into plasmid
pcDNA 3.1 placing the genes under the transcriptional
control of the human cytomegalovirus (CMV) immediate-early promoter. Recombinant plasmids were purified by CsCl gradient separation, concentrated by
ethanol precipitation, dissolved in distilled water and
stored at 208C. The concentration and purity of DNA
were determined by spectrophotometric methods and
by agarose gel electrophoresis, respectively.

Synthesis of non-ionic block copolymers
Copolymers were produced by ring opening addition
polymerisation with two or more monomers, added in
predetermined sequences and amounts. The high mol.
wt non-ionic block copolymers used for these studies
were synthesised from propylene oxide and ethylene
oxide with propylene glycol as the initiator and a
proprietary base catalysed process. Copolymers were
produced based on 11- (CRL 1029) and 15- (CRL
1190) kDa POP internal cores with POE 5% end
blocks, POE-POP-POE.

Transient expression of gB and gD
Vero cells were transfected with gB plasmid constructs
by a procedure based on a modification of the calcium
phosphate method [32, 34]. Briefly, Vero cells were
grown to 50–70% confluence in 25-cm2 tissue-culture
flasks. Purified plasmid DNA (15 ìg) was suspended in
0.5 ml of double-distilled water containing 250 mM
CaCl2 . Subsequently, 0.5 ml of a solution consisting
of 23 BBS – 50 mM BES (N, N-bis[2-hydroxyethyl]-2aminoethanesulphonic acid, Sigma; 280 mM NaCl;
1.5 mM Na2 HPO4 ; pH 6.95) – was added in a drop-wise
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fashion. The mixture was allowed to incubate at room
temperature for 15–30 min. Medium was removed
from the cells and 2 ml of DEAE dextran (Sigma)
500 mg=ml in Tris-buffered saline (TBS: NaCl 0.85%,
0.25 M Tris, pH 7.4) were added and incubated for
2 min at room temperature. The DEAE was removed
by aspiration, and the DNA mixture was brought up to
3 ml with DMEM and added to the flasks. The cells
were incubated for 4–5 h at 378C in air with CO2 5%.
The medium was removed and cells were subjected to
glycerol shock for 2 min (2 ml of glycerol 15% in
TBS). Cells were washed with TBS, 5.0 ml of fresh
medium were added and they were incubated for 40 h
at 378C in CO2 5%.

Indirect immunofluorescence assays (IFA)
The IFA was conducted on transfected Vero cells 48 h
after transfection or Vero cells infected with HSV-1.
For transfection, Vero cells were seeded on coverslips
in 24-well plates and transfected with DNA 2 ìg=
coverslip as described above. Vero cells were infected
with the virus at a multiplicity of infection (m.o.i.) of
2; 24 h after infection, cells were harvested by gently
tapping the sides of the flask thereby allowing the cells
to become suspended in the medium. The cells were
washed three times in PBS, pelleted by centrifugation
at 1000 rpm for 5 min and placed in individual wells on
12-well teflon-coated glass slides. The slides were
allowed to dry, cells were fixed with methanol for
30 min, blocked for 30 min with goat serum 10% in
phosphate-buffered saline (PBS) at room temperature
in a humidified chamber, and then incubated for 1 h
with primary antibodies. After three washes with PBS,
fluorescein-conjugated goat anti-mouse IgG (H&L
chains, Organon Teknika-Cappel, Durham, NC, USA)
was added at a 1 in 40 dilution in blocking buffer. The
slides were incubated for 1 h, counterstained with
Evans Blue 0.01%, washed, dried, mounted and
examined with a Zeiss microscope equipped with a
halogen source and epifluorescence illuminator.

Radiolabelling and immunoprecipitation
Confluent Vero cell monolayers were infected at an
m.o.i. of 2. Infected cells were labelled with [35 S]methionine, 50 ìCi=ml of methionine-free medium, for
6–24 h after infection [32]. After labelling, cells were
washed three times with PBS and pelleted by centrifugation. Proteins were extracted from radiolabelled
cells with Nonidet P-40 1% and sodium deoxycholate
0.5% in lysis buffer (50 mM Tris-buffer, 50 mM NaCl,
phenylmethyl-sulphonyl fluoride 100 ìg=ml, aprotinin
10 ìg=ml) and stored at 208C until used. The cell
lysates from either transfection or infection experiments were mixed with mouse serum from animals
immunised with gB or gD plasmids or with MAbs
against gB and gD generated in this laboratory for 1 h
at 48C and rocked continuously. Protein A-Sepharose
(5 ìg) in 200 ml of lysis buffer was then added to the

mixtures and incubated for 1.5 h at 48C under similar
conditions. The sepharose beads were washed three
times with lysis buffer. Samples were then placed in
electrophoresis loading buffer (SDS 2%, 2-mercaptoethanol 4%, 50 mM Tris, pH 8, bromophenol blue
0.0005%), boiled for 5 min and electrophoresed in
SDS-polyacrylamide gels [32].

Genetic immunisation of mice
Mice (five animals per group) were immunised with
plasmids containing HSV-1 gB or gD. Plasmid DNA
(50 ìg), alone or mixed with copolymers, was introduced into each animal either i.m. or i.p. All inoculations were performed with a 1-ml syringe and a
25-gauge needle in a total volume of 200 ìl. Animals
were given booster immunisations twice at 3–4 week
intervals. Three weeks after the last boost, the animals
were bled and antibody responses against gB and gD
were evaluated by immunofluorescence and radioimmunoprecipitation (RIP) assays. Two control groups
of mice were immunised with 1 3 105 HSV-1 (KOS)
virus and vector plasmid DNA containing no insert,
respectively.

Infection of mice by scarification
A location on the back of hairless mice or BALB/c
mice between the third and fourth lumbar vertebrae,
shaved with a hair-clipper, was scarified with a blunted
18-gauge needle (six scratches) giving a cross-hatch
pattern. The scarified area was c. 1 cm in diameter and
20 ìl of HSV-1 (ABGK-1) virus stock containing c.
2:5 3 104 plaque-forming units (pfu) were applied to it
with a pipettor and rubbed with the side of the tip.
Each treatment group contained five animals. The
degree of infection in mice was readily scored by
mortality rates and estimating the severity and extent of
the lesion on a scale 0–4. Animals were examined
daily for mortality and development of lesions.

Results
Transient expression of gB and gD in Vero cells
To confirm the expression of the recombinant plasmids
carrying the gB and gD genes, Vero cells were
transfected with the corresponding plasmids and their
glycoprotein expressions were detected by IFA with
MAbs to gB and gD. Up to 10% of the transfected cells
expressed gB and gD throughout their cytoplasm (Fig.
1).

Assessment of antibodies in mice immunised with
the gB or gD genes
Blood from individual mice inoculated with gB or gD
plasmid with or without non-ionic block copolymers
via the i.m. or i.p. routes were collected 3 weeks after
the final immunisation. IFA and immunoprecipitation

DNA-MEDIATED IMMUNISATION WITH HSV-1 gB AND gD

353
35

assays with HSV-1-infected Vero cells or their Slabelled extracts were used to assess the reactivity of
the sera against their respective antigens. Four of five
mice inoculated with 50 ìg of gD plasmid alone or gD
plasmid mixed with CRL 1029 generated high anti-gD
antibody responses. Similarly, all five mice inoculated
with the mixture of gD plasmid and CRL 1190
produced high levels of anti-gD antibodies. In contrast,
i.p. injections of either gD and CRL 1029, or gD and
CRL 1190 did not induce any detectable antibody
responses (Fig. 2). Similar experiments were performed
with the gB-expressing plasmid. When gB immunisations were performed via the i.m. route, all three mice
inoculated with the gB plasmid alone developed high
levels of anti-gB antibodies. Similarly, all five mice
inoculated with a mixture of gB and poloxamer 1029
generated high levels of gB-specific antibodies. Mice
inoculated with gB and poloxamer 1190 appeared to
elicit slightly higher levels of anti-gB antibodies when
their sera were tested by RIP (Fig. 3) followed by
densitometric analysis of SDS-PAGE autoradiograms
(results not shown). Mice inoculated i.p. with gB and
poloxamer 1190 developed weak humoral immune
responses against gB, whereas mice inoculated with
mixtures of gB and CRL 1029 did not produce any
anti-gB antibody (Fig. 3). The results of antibody
responses were similar in both strains of mice.
Therefore, the evaluation of antibody by RIP presented
in Fig. 3 pertains to sera from BALB/c mice.
Fig. 1. Expression of gB and gD in Vero cells. Vero cells
seeded on coverslips were transfected with plasmids containing
gB or gD and MAbs to gB and gD were used to detect the
expression of the plasmids. (a) Reaction of combined MAbs to
gB and gD with mock transfected cells (plasmid without
insert); (b) Vero cells transfected with plasmid containing gB
and treated with anti-gB MAb; (c) Vero cells transfected with
plasmid containing gD and treated with anti-gD MAb.

Protection of vaccinated hairless mice against
lethal challenge with HSV-1
Vaccinated mice were challenged with the clinical
isolate ABGK-1 and the course of infection was
monitored at c. 12-h intervals. Initial lesions were

Fig. 2. Assessment of humoral immune responses against gD by RIP. Vero cells were infected with HSV-1 (KOS) at m.o.i. of 2 and
labelled with 35 S-methionine from 6 to 24 h after infection. Cell lysates were mixed with individual or pooled sera from mice
immunised with plasmid containing gD. The protein A-sepharose-precipitated proteins were separated electrophoretically in SDSpolyacrylamide 10% gel and processed for autoradiography. Identification of lanes is displayed on top of each lane.
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Fig. 3. Assessment of humoral immune responses against gB by RIP. Vero cells were infected with HSV-1 (KOS) at m.o.i. of 2 and
labelled with 35 S-methionine from 6 to 24 h after infection. Cell lysates were mixed with individual or pooled sera from mice
immunised with plasmid containing gB. The protein A-sepharose-precipitated proteins were separated electrophoretically in SDSpolyacrylamide 10% gel and processed for autoradiography. Identification of lanes is displayed on top of each lane.

punctate and progressed to form erosions in the area of
the dermatome. These lesions enlarged within 3–10
days and at later stages of the infection formed
unilateral band-like lesions which subsequently ulcerated. In animals that recovered, lesions healed within
2–3 weeks. In most cases, unprotected animals developed paralysis of the lower legs, which preceded
systemic infection and death. Four of five mice in a
control group, which was mock-vaccinated (naive
mice), developed lesions and were initially paralysed
7–14 days after infection, followed by death. The fifth
mouse developed lesions at day 13 and died 21 days
after infection. Ultimately, none of these mice survived
the HSV-1 infection (Fig. 4 and Table 1). In the group
immunised i.m. with gD plasmid alone (four mice),
one mouse developed lesions 12 days after infection
and died 2 days later. Two of the remaining three mice
developed small lesions which healed later (Fig. 4 and
Table 1). None of the four mice immunised i.m. with
gD plasmid mixed with either CRL 1029 or CRL 1190
developed lesions and they all survived the HSV-1
lethal challenge infection. A control group of mice was
immunised by inoculation i.p. with 5 3 104 pfu of
HSV-1 KOS strain/mouse 2 months before the skin
infection. Animals in this group developed small
lesions, which ultimately healed, and all animals
survived the infection (Fig. 4 and Table 1).

developed small lesions which later healed. All the
mice in groups which were vaccinated i.m. with gD
alone or gD mixed with the copolymers CRL 1029 and
1190 were protected against the lethal challenge with
HSV-1 (Fig. 4 and Table 2). All of the mice immunised
with gD alone by i.p. injection succumbed to the lethal
challenge (Table 2). However, two mice immunised
with gD plasmid mixed with CRL 1029 by i.p.
injection developed small lesions which resolved later
and the mice survived (Table 2). Of the remaining
mice, two died 9 days after infection and one mouse
died 15 days after infection (Table 2). Mice immunised
by i.m. injection with gB alone or gB mixed with either
CRL 1029 or CRL 1190 were all protected and
survived the HSV-1 challenge, although mice vaccinated with gB mixed with CRL 1190 developed lesions
which later resolved (Fig. 4 and Table 2). However,
vaccination by i.p. injection was not as effective. One
of five mice immunised i.p. with gD plasmid mixed
with CRL 1190 developed a limited lesion which later
resolved and the mouse survived the infection. Of the
remaining four mice, three mice died at 10 days and
one mouse died 14 days after infection (Table 2). None
of the mice immunised with gB plasmid alone by i.p.
injection survived the infection. In contrast, three of
four mice immunised i.p. with gB mixed with CRL
1190 survived the infection (Table 2).

Protection of vaccinated BALB/c mice against
lethal challenge with HSV-1

Discussion

None of the animals in the mock-immunised control
group survived the HSV-1 challenge (Fig. 4 and Table
2). A second control group of mice was immunised by
inoculation i.p. of 5 3 104 pfu of HSV-1 KOS strain/
mouse 2 months before the skin infection. All animals
in this group survived the infection; however, all

The results of this study show that DNA-based
vaccines consisting of plasmids capable of expressing
HSV-1 glycoproteins gB and gD induced strong immune responses that protected mice against lethal
challenge with HSV-1. Furthermore, non-ionic block
copolymers seemed to enhance humoral and protective
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Fig. 4. Photographs of different groups of hairless and BALB/c mice in the vaccination trial. Each group of hairless mice consisted of four mice except the untreated and immunised groups which had
five mice. Two hairless mice and three BALB/c mice in naı̈ve control groups as well as one mouse in the ‘gD alone’ treated group died early and became blackened such that the lesions were not clear
in the photographs; therefore, they were excluded from the photographs.
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Table 1. HSV-1 lethal challenge of immunised hairless
mice
Experimental groups
Naive control
HSV-1 immunised
gD alone
gD plus 1029
gD plus 1190

Route
...
i.p.
i.m.
i.m.
i.m.

Survived=dead
(% protection)
0=5
5=5
3=4
5=5
5=5

(0)
(100)
(75)
(100)
(100)

immune responses generated by gB and gD plasmidbased vaccines when given by i.p. injection.
Gene vaccination of BALB/c and SKH-1 mice with the
gB and gD genes induced high levels of antibody
responses against gB and gD. Furthermore, the induction of humoral responses was dependent on the
route of immunisation. Generally, the i.m. route of
DNA vaccination consistently produced higher levels of
humoral responses than the i.p. route. These responses
protected mice from lethal challenge with HSV-1 via
skin scarification, which resembles the zosteriform
model and is different from a previous study, where the
challenge was given by systemic injection (i.p.) of an
HSV-2 strain [25]. It is possible that the high amounts
of plasmid DNA used in the present study produced
maximum levels of humoral responses to gB and gD in
the absence of poloxamers and, therefore, obscured
poloxamer-mediated enhancement of humoral responses. It is worth noting that higher levels of
humoral immunity and protection were produced in
this study than in similar experiments by other
investigators, in which gB gene was studied and only
80% of the mice immunised with the gB-expressing
plasmid survived a lethal HSV-1 challenge [35]. Other
studies showed that DNA vaccination with HSV-1 or
HSV-2 gB or gD genes protected mice or guinea-pigs
against systemic or vaginal infections, respectively
[6, 7, 25, 26]. This study, for the first time, showed that
both gB and gD genes protected the mice against a
zosteriform infection in a mouse model and the BALB/
c mouse was as good a model as the hairless mouse for
formation of zosteriform lesions.
Table 2. HSV-1 lethal challenge of immunised BALB/c
mice
Experimental groups

Route

Survived=dead
(% protection)

Naive control
HSV-1 immunised
gD alone
gD plus 1029
gD plus 1190
gD alone
gD plus 1029
gD plus 1190

...
i.p.
i.p.
i.p.
i.p.
i.m.
i.m.
i.m.

0=5
5=5
0=5
2=5
1=5
5=5
5=5
4=4

(0)
(100)
(0)
(40)
(20)
(100)
(100)
(100)

gB
gB
gB
gB
gB

i.p.
i.p.
i.m.
i.m.
i.m.

0=5
3=5
5=5
5=5
4=4

(0)
(60)
(100)
(100)
(100)

alone
plus 1190
alone
plus 1029
plus 1190

The results also showed that, contrary to the i.m. route
with high protection efficiency, introduction of gB or
gD plasmid alone by i.p. injection did not protect the
animals against the HSV-1 challenge. This failure to
elicit immune responses by i.p. injection correlated
with the absence of antibody production against gB
or gD. By contrast, co-administration of gB or gD
plasmids with copolymers by i.p. injection provided
some protection against lethal herpes infection, which
was consistent with the ability of these mixtures to
elicit humoral immune responses. It can be suggested
that copolymers, by binding to the DNA, may facilitate
its uptake by the resident macrophages where it can be
expressed and be presented to the immune system for
elicitation of protective cellular and humoral immune
responses.
Genetic immunisation with a combination of HSV
genes, such as those of gB and gD, will produce an
effective vaccine alternative to other available methods.
Protection of vaccinated mice against HSV-1 challenge
was 100% with either gB or gD. Moreover, further
study is needed to document if lower amounts of DNA
in combination with non-ionic block copolymers would
enhance the efficacy of DNA-based vaccination.
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